A Phase 2 Interventional, Multicenter, Randomized Open Label Study to Determine the Effective and Tolerable Dose of KAF156 and Lumefantrine Solid Dispersion Formulation in Combination, Given Once Daily for 1, 2 and 3-days to Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
Phase of Trial: Phase II
Latest Information Update: 25 Oct 2017
At a glance
- Drugs KAF 156 (Primary) ; Lumefantrine
- Indications Falciparum malaria
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 21 Aug 2017 According to a Novartis media release, Dr. Bakary Fofana is the clinical trial investigator at the Malaria Research and Training Center in Bougoula - Hameau.
- 21 Aug 2017 According to a Novartis media release, the first trial center is operational in Mali and will be followed by sixteen additional centers across a total of nine countries in Africa and Asia over the next few months.
- 21 Aug 2017 Status changed from not yet recruiting to recruiting, according to a Novartis media release.